貝達藥業(300558.SZ)擬以3.85億元認購禾元生物新發行的Pre-IPO輪普通股
格隆匯3月4日丨貝達藥業(300558.SZ)公佈,公司第三屆董事會第二十九次會議審議通過《關於投資武漢禾元生物科技股份有限公司暨關聯交易的議案》,公司擬以3.85億元人民幣的自有資金按每股19.24元的價格認購武漢禾元生物科技股份有限公司(“禾元生物”或“標的公司”)新發行的Pre-IPO輪普通股2001.0395萬股。同時,公司關聯人杭州貝銘股權投資基金合夥企業(有限合夥)(“貝銘基金”)擬出資8000萬元人民幣以相同價格認購禾元生物新發行Pre-IPO輪普通股415.8004萬股。
公吿顯示,禾元生物是一家專門從事植物源重組蛋白表達技術研究與產品開發的國家高新技術企業,已建立“水稻胚乳細胞重組蛋白表達技術平台(OryzHiExp)”和“重組蛋白純化技術平台(OryzPur)”兩大技術平台,開發了以植物源重組人血清白蛋白注射液(HY1001)為代表的一系列植物源新藥產品管線,及多種用於各類細胞培養及美粧領域的重組細胞生長因子和重組蛋白。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.